New oral medications to target proteins in prostate cancer
Official title: Orally active CBP/p300 degraders
Funded at University of Michigan at Ann Arbor · NIH-11046643 · Data updated 2026-11-12
This study is looking at new oral medications that could help fight advanced prostate cancer by breaking down certain proteins that help cancer cells grow, and it's testing these treatments in animals to see how well they work and if they're safe for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $672,792 |
| NIH project number | 5R01CA289013-02 |
| Project ID | NIH-11046643 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with androgen-independent or androgen-resistant prostate cancer.
✕Less likely to help
Patients with early-stage prostate cancer or those not resistant to androgen therapy may not benefit from this research.
What this research studies
This research focuses on developing new oral medications that can effectively degrade specific proteins (CBP and p300) involved in the growth of prostate cancer cells. By creating small-molecule degraders, the research aims to provide a more potent treatment option compared to existing therapies. The approach involves testing these degraders in animal models to evaluate their effectiveness in inhibiting tumor growth and their safety profile. If successful, these medications could offer a novel way to treat patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and convenient treatment options for patients with prostate cancer.
How similar studies have gone: Other research has shown promising results with similar approaches targeting protein degradation in cancer therapy, indicating potential for success.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Wang, Shaomeng — University of Michigan at Ann Arbor
- Study coordinator: Wang, Shaomeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.